The total number of records retrieved from this search are 60. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_861	Virus nameHerpes simplex virus	Virus strainBL1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineTriple-negative breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result75 % cancerous cell killing after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID12595888
IDOV_864	Virus nameHerpes simplex virus	Virus strainBL1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineTriple-negative breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result92% cancerous cell killing after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID12595888
IDOV_867	Virus nameHerpes simplex virus	Virus strainBL1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineTriple-negative breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result40 % cancerous cell killing after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID12595888
IDOV_870	Virus nameHerpes simplex virus	Virus strainBL1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineTriple-negative breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result80% cancerous cell killing after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID12595888
IDOV_873	Virus nameHerpes simplex virus	Virus strainJS1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineTriple-negative breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result85 % cancerous cell killing after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID12595888
IDOV_876	Virus nameHerpes simplex virus	Virus strainJS1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineTriple-negative breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result96% cancerous cell killing after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID12595888
IDOV_879	Virus nameHerpes simplex virus	Virus strainJS1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineTriple-negative breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result60 % cancerous cell killing after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID12595888
IDOV_882	Virus nameHerpes simplex virus	Virus strainJS1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineTriple-negative breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result88% cancerous cell killing after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID12595888
IDOV_2442	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2443	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2444	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2445	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after day 7	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2446	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after day 9	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2482	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.10 MOI	In-vitro result90% cell survival after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2483	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.10 MOI	In-vitro result90% cell survival after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2484	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.10 MOI	In-vitro result90% cell survival after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2485	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.10 MOI	In-vitro result90% cell survival after day 7	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2518	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration1 MOI	In-vitro result70% cell survival after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2519	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration1 MOI	In-vitro result10% cell survival after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2520	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration1 MOI	In-vitro result10% cell survival after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2521	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration1 MOI	In-vitro result10% cell survival after day 7	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2579	Virus nameAdenovirus	Virus strainCNHK600-IL24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and addition of IL-24 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai laboratory animal center, China	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectNA	Clinical trialNA	PMID22640485
IDOV_2580	Virus nameAdenovirus	Virus strainCNHK600-IL24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and addition of IL-24 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai laboratory animal center, China	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result100% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectNA	Clinical trialNA	PMID22640485
IDOV_2581	Virus nameAdenovirus	Virus strainCNHK600-IL24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and addition of IL-24 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai laboratory animal center, China	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result50% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectNA	Clinical trialNA	PMID22640485
IDOV_2582	Virus nameAdenovirus	Virus strainCNHK600-IL24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and addition of IL-24 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai laboratory animal center, China	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result20% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectNA	Clinical trialNA	PMID22640485
IDOV_2583	Virus nameAdenovirus	Virus strainCNHK600-IL24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and addition of IL-24 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai laboratory animal center, China	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1000 MOI	In-vitro result10% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectNA	Clinical trialNA	PMID22640485
IDOV_2584	Virus nameAdenovirus	Virus strainCNHK600-IL24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and addition of IL-24 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai laboratory animal center, China	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10000 MOI	In-vitro resultAll cells are dead	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectNA	Clinical trialNA	PMID22640485
IDOV_2585	Virus nameAdenovirus	Virus strainCNHK600-IL24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and addition of IL-24 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai laboratory animal center, China	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismNu/Nu female mice orthotopic for MDA-MB-231 cell line (8.0E+7 cells)	In-vivo virus concentration1.0E+8 pfu	In-vivo toxicityNA	In-vivo resultTumor volume comes to 1000mm as compared to normal 2000 after 42 days	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectNA	Clinical trialNA	PMID22640485
IDOV_2586	Virus nameAdenovirus	Virus strainCNHK600-IL24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and addition of IL-24 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai laboratory animal center, China	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismNu/Nu female mice orthotopic for MDA-MB-231 cell line (8.0E+7 cells)	In-vivo virus concentration2.0E+8 pfu	In-vivo toxicityNA	In-vivo resultTumor volume comes to below 1000mm as compared to normal 2000 after 42 days	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectNA	Clinical trialNA	PMID22640485
IDOV_2587	Virus nameAdenovirus	Virus strainCNHK600-IL24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and addition of IL-24 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai laboratory animal center, China	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismNu/Nu female mice orthotopic for MDA-MB-231 cell line (8.0E+7 cells)	In-vivo virus concentration4.0E+8 pfu	In-vivo toxicityNA	In-vivo resultTumor volume comes to 500mm as compared to normal 2000 after 42 days	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectUpregulation of GADD34	Clinical trialNA	PMID22640485
IDOV_2632	Virus nameAdenovirus	Virus strainSG500-dNK	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of deoxyribonucleoside kinase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result80% cell survival after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombination of drug and virus increase the apoptosis process	Immunogenic effectNA	Clinical trialNA	PMID23000515
IDOV_2633	Virus nameAdenovirus	Virus strainSG500-dNK	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of deoxyribonucleoside kinase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result60% cell survival after 6 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombination of drug and virus increase the apoptosis process	Immunogenic effectNA	Clinical trialNA	PMID23000515
IDOV_2636	Virus nameAdenovirus	Virus strainSG500-dNK	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of deoxyribonucleoside kinase	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with drug Bvdu (1 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result70% cell survival after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombination of drug and virus increase the apoptosis process	Immunogenic effectNA	Clinical trialNA	PMID23000515
IDOV_2637	Virus nameAdenovirus	Virus strainSG500-dNK	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of deoxyribonucleoside kinase	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with drug Bvdu (1 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result30% cell survival after 6 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombination of drug and virus increase the apoptosis process	Immunogenic effectNA	Clinical trialNA	PMID23000515
IDOV_2638	Virus nameAdenovirus	Virus strainSG500-dNK	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of deoxyribonucleoside kinase	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with drug dFdC (1 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result60% cell survival after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombination of drug and virus increase the apoptosis process	Immunogenic effectNA	Clinical trialNA	PMID23000515
IDOV_2639	Virus nameAdenovirus	Virus strainSG500-dNK	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of deoxyribonucleoside kinase	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with drug dFdC (1 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result20% cell survival after 6 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombination of drug and virus increase the apoptosis process	Immunogenic effectNA	Clinical trialNA	PMID23000515
IDOV_2644	Virus nameAdenovirus	Virus strainSG500-dNK	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of deoxyribonucleoside kinase	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with drug Bvdu (1 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.001 MOI	In-vitro result80% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombination of drug and virus increase the apoptosis process	Immunogenic effectNA	Clinical trialNA	PMID23000515
IDOV_2645	Virus nameAdenovirus	Virus strainSG500-dNK	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of deoxyribonucleoside kinase	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with drug Bvdu (1 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result80% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombination of drug and virus increase the apoptosis process	Immunogenic effectNA	Clinical trialNA	PMID23000515
IDOV_2646	Virus nameAdenovirus	Virus strainSG500-dNK	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of deoxyribonucleoside kinase	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with drug Bvdu (1 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result60% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombination of drug and virus increase the apoptosis process	Immunogenic effectNA	Clinical trialNA	PMID23000515
IDOV_2647	Virus nameAdenovirus	Virus strainSG500-dNK	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of deoxyribonucleoside kinase	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with drug Bvdu (1 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result50% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombination of drug and virus increase the apoptosis process	Immunogenic effectNA	Clinical trialNA	PMID23000515
IDOV_2648	Virus nameAdenovirus	Virus strainSG500-dNK	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of deoxyribonucleoside kinase	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with drug Bvdu (1 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result40% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombination of drug and virus increase the apoptosis process	Immunogenic effectNA	Clinical trialNA	PMID23000515
IDOV_2649	Virus nameAdenovirus	Virus strainSG500-dNK	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of deoxyribonucleoside kinase	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with drug dFdC (1 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.001 MOI	In-vitro result80% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombination of drug and virus increase the apoptosis process	Immunogenic effectNA	Clinical trialNA	PMID23000515
IDOV_2650	Virus nameAdenovirus	Virus strainSG500-dNK	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of deoxyribonucleoside kinase	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with drug dFdC (1 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result70% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombination of drug and virus increase the apoptosis process	Immunogenic effectNA	Clinical trialNA	PMID23000515
IDOV_2651	Virus nameAdenovirus	Virus strainSG500-dNK	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of deoxyribonucleoside kinase	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with drug dFdC (1 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result40% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombination of drug and virus increase the apoptosis process	Immunogenic effectNA	Clinical trialNA	PMID23000515
IDOV_2652	Virus nameAdenovirus	Virus strainSG500-dNK	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of deoxyribonucleoside kinase	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with drug dFdC (1 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result20% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombination of drug and virus increase the apoptosis process	Immunogenic effectNA	Clinical trialNA	PMID23000515
IDOV_2653	Virus nameAdenovirus	Virus strainSG500-dNK	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of deoxyribonucleoside kinase	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with drug dFdC (1 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result10% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombination of drug and virus increase the apoptosis process	Immunogenic effectNA	Clinical trialNA	PMID23000515
IDOV_2664	Virus nameAdenovirus	Virus strainSG500-dNK	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of deoxyribonucleoside kinase	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with drug dFdC (1 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for MDA-MB-231(5.0E+6 cells)	In-vivo virus concentration1.0E+9 pfu	In-vivo toxicityNA	In-vivo resultIncrease in median survival time to more than 100 days compared to control and reduction in tumor volume 663.85 +/- 379.39mm compared to control 1336.46 +/- 614.81	Mode of deliveryNA	Pathway inducedCombination of drug and virus increase the apoptosis process	Immunogenic effectNA	Clinical trialNA	PMID23000515
IDOV_2938	Virus nameNewcastle disease virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman mammary cancer cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2⁴.⁷ HAU/ml	In-vitro resultCell viability reduced below 20%	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay (44.52 +/- 10.13) after 72 hours	Immunogenic effectNA	Clinical trialNA	PMID25821783
IDOV_4301	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast adenocarcinoma	Cell lineMDA-MB-231	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 pfu	In-vitro result58.9 % cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_5043	Virus nameVaccinia virus	Virus strainVG9	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast adenocarcinoma cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result40% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5044	Virus nameVaccinia virus	Virus strainVG9	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast adenocarcinoma cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result30% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5045	Virus nameVaccinia virus	Virus strainVG9	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast adenocarcinoma cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result20% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5046	Virus nameVaccinia virus	Virus strainVG9-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast adenocarcinoma cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result30% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5047	Virus nameVaccinia virus	Virus strainVG9-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast adenocarcinoma cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result30% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5048	Virus nameVaccinia virus	Virus strainVG9-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast adenocarcinoma cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result20% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5049	Virus nameVaccinia virus	Virus strainWR-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast adenocarcinoma cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result30% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5050	Virus nameVaccinia virus	Virus strainWR-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast adenocarcinoma cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result30% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5051	Virus nameVaccinia virus	Virus strainWR-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast adenocarcinoma cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result20% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5377	Virus nameMaraba virus	Virus strainMG1	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman triple negative breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell lineNA	In-vitro toxicityNA	AssayCoomassie brilinat blue staining	In-vitro virus concentration4 micromolar	In-vitro result80% cell viable after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialIn clinical trial for various cancer cell line	PMID27503504
IDOV_5380	Virus nameMaraba virus	Virus strainMG1	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 2 micromolar palcitaxel for 48 hours	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman triple negative breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell lineNA	In-vitro toxicityNA	AssayCoomassie brilinat blue staining	In-vitro virus concentration4 micromolar	In-vitro result30% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectLevel of IFN beta production does not effected by combination	Clinical trialIn clinical trial for various cancer cell line	PMID27503504